Ipamorelin is not FDA-approved, banned in sport, and quietly dropped from the compounding list in 2024 — here is what the studies actually measured.

The short version

Let's get the obvious out of the way first: this site is called Shop Ipamorelin and it sells nothing. No cart, no vendor, no price. It's a research zine about a peptide whose marketing has badly outrun its evidence, and the regulatory story is the headline.

Ipamorelin is a small synthetic peptide — five amino acids — that tells the pituitary gland to release a pulse of growth hormone (GH). It does that cleanly: unlike older peptides in its class, it barely touches the stress hormone cortisol or the hormone prolactin. That selectivity is the one genuinely interesting thing about it.

Here's the part the supplement pages skip. Ipamorelin has never been approved as a drug, anywhere. Its single human trial failed. In 2024 the FDA pulled it from the list pharmacies could legally compound from. It's banned in sport. The honest research is real but thin, and what people report — including the downsides — is on the effects page.

Status first: never approved, recently restricted, banned in sport

Ipamorelin has never been approved as a drug by the FDA, the EMA, or any other regulator ^[13]. That's not a paperwork backlog. The only published Phase 2 trial — postoperative ileus, the sluggish-bowel condition after surgery — missed its primary endpoint and the program stopped there ^[3].

The classification matters because the gray market loves to imply otherwise. Ipamorelin is a research chemical: lab material sold "for research use only," not a finished medicine, and not the same thing as a prescription drug product. Anyone selling it as a treatment is selling past the data.

In 2024 the regulatory ground shifted again. The FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list — the list that governs what compounding pharmacies can legally make — after the nominator withdrew it, and reviewed both the acetate and the free base at the October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) meeting. Translation: a legal path that used to exist got narrower. The full breakdown is on the is ipamorelin fda approved page.

And in sport, it's prohibited at all times under WADA category S2 (growth hormone secretagogues), with established urine tests to catch it.

What ipamorelin actually is

Ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2; also catalogued as NNC 26-0161) is a synthetic pentapeptide — a chain of five amino acids built in a lab, not made by the human body ^[1]. It's a growth hormone secretagogue (GHS): a compound that prods the pituitary into secreting growth hormone. It does this by switching on the GHS-R1a receptor — the same docking site the body's natural "hunger hormone" ghrelin uses ^[1].

Novo Nordisk discovered it in the 1990s. Its founding 1998 paper gave it the title that stuck: "the first selective growth hormone secretagogue" ^[1]. Selective is the operative word — in rats and swine it released GH as strongly as the older peptide GHRP-6 but, even at doses more than 200 times its GH threshold, it didn't push up the stress hormones ACTH and cortisol ^[1].

This is a pure-ipamorelin site. It is not the popular CJC-1295 + ipamorelin combination, though we cover that pairing where the questions demand it. Where a study used a different GHS peptide as a stand-in for the class, we say so.

The data that survives scrutiny

Strip away the marketing and a short, honest record remains. In healthy men, a human pharmacokinetics study measured a terminal half-life of about 2 hours and a single GH pulse peaking roughly 40 minutes after dosing ^[2]. In adult rats, 15 days of subcutaneous dosing raised the longitudinal bone-growth rate from 42 to 52 micrometers per day at the top dose — without moving systemic IGF-1, the liver-made messenger that carries many GH effects ^[4].

The freshest finding is a 2024 ferret study: ipamorelin blunted chemotherapy-driven weight loss by about 24% in the delayed phase, but did nothing for nausea ^[5]. That's a real, recent, peripheral effect — and a useful reminder that the interesting signals here are metabolic and tissue-level, not the miracle anti-aging story the ads tell. The full mechanism and study set live on the Ipamorelin research page.

What this site is — and what it refuses to be

This is editorial commentary on published science, written for a curious adult, not a scientist. Every number on the site is cited to a real study you can pull up yourself on the Ipamorelin references page.

What it won't do: recommend a human dose, promise a result, name a competing brand, or point you at a checkout. The dosage page describes what was given to which animal at which dose by which route — research context, full stop. The effects page reports what the research-use community describes, clearly stamped as anecdote, alongside cited safety reasoning.

The joke in the domain name is the whole thesis. You came to shop. There's nothing here but the paper trail — which, on a compound this over-sold, is the most useful thing we could hand you.